A Randomized Double Blind Placebo And Active Controlled Parallel Group Phase 2 Study To Evaluate PF-05089771 As A Monotherapy And As An Add-on To Pregabalin For The Treatment Of Painful Diabetic Peripheral Neuropathy

Trial Profile

A Randomized Double Blind Placebo And Active Controlled Parallel Group Phase 2 Study To Evaluate PF-05089771 As A Monotherapy And As An Add-on To Pregabalin For The Treatment Of Painful Diabetic Peripheral Neuropathy

Completed
Phase of Trial: Phase II

Latest Information Update: 10 May 2017

At a glance

  • Drugs PF 5089771 (Primary) ; Pregabalin
  • Indications Diabetic neuropathies; Pain
  • Focus Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 02 Nov 2015 Status changed from recruiting to completed as reported by ClinicalTrial.gov record.
    • 20 Nov 2014 Planned End Date changed from 1 Apr 2017 to 1 May 2017 as reported by ClinicalTrial.gov record.
    • 20 Nov 2014 Planned primary completion date changed from 1 Apr 2017 to 1 May 2017 as reported by ClinicalTrial.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top